Emcure Pharmaceuticals shares hit a record high after rising 16% in two sessions, following strong Q2FY27 results. Profit increased 29% and revenue grew 24%. Jefferies and Kotak retained Buy ratings, citing growth prospects and setting target prices of ₹2,500 and ₹2,450.